AUTHOR=Xiao Huiyuan , Huang Wen , Li Yanlei , Zhang Rongxin , Yang Long 

TITLE=Targeting Long Non-Coding RNA TTN-AS1 Suppresses Bladder Cancer Progression

JOURNAL=Frontiers in Genetics

VOLUME=Volume 12 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.704712

DOI=10.3389/fgene.2021.704712

ISSN=1664-8021

ABSTRACT=Abstract
Backgroud:
To explore the biological and clinical effects of titin-antisense RNA1(TTN-AS1) in bladder cancer (BLCA), and the association between TTN-AS1 and Activating transcription factor 2 (ATF2) in BLCA.
Methods:
Kaplan-Meier method was performed to analyze the association between the expression of TTN-AS1 and prognosis of BLCA patients from TCGA dataset and our institution. Quantitative real-time PCR (RT-PCR) was conducted to explore the expression of TTN-AS1 between the patients underwent TURBT and Re-TURBT. MTT assay, Colony formation assay and tumor formation assay was conducted to evaluate the effect of TTN-AS1 on the ability of proliferation  in BLCA cell lines. Transwell assay was performed to evaluate the effect of TTN-AS1 on the ability of invasion in BLCA cell lines. Bioinfomatics and Immunohistochemical (IHC) staining was used to relationship between TTN-AS1 and ATF2.
Results:
The higher expression of TTN-AS1 was related with poorer disease free survival (DFS) in patients with BLCA. And the expression of TTN-AS1 was higher in BLCA patients who underwent Re-TURBT compared BLCA patients who underwent TURBT. Knocking down TTN-AS1 was resulted in inhibiting the ability of proliferation and invasion of bladder cancer cells.The ATF2 may serves as a downstream target of TTN-AS1 in bladder cancer, and the high expression of ATF2 was also related with adverse disease-free survival.
Conclusion:
Our study reveal that TTN-AS1 which served as an oncogene by activating ATF2 in BLCA. The findings suggested that TTN-AS1 may acts as a novel therapeutic target for patients with BLCA.